An Enzyme Linked Immunosorbent Assay (ELISA) for Monitoring Galactosemia

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$153,311.00
Award Year:
2007
Program:
STTR
Phase:
Phase I
Contract:
1R41DK076481-01A1
Award Id:
85560
Agency Tracking Number:
DK076481
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
VANDALIA RESEARCH, INC., 940 4TH AVE, STE 350, HUNTINGTON, WV, 25701
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
611002218
Principal Investigator:
MENASHI COHENFORD
(304) 529-0803
COHENFORD@MARSHALL.EDU
Business Contact:
() -
gregg@vandaliaresearch.com
Research Institute:
MARSHALL UNIVERSITY

MARSHALL UNIVERSITY
401 11TH STREET, SUITE 1400
HUNTINGTON, WV, 25701-4899

Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): The long term objective of this proposal is to develop a diagnostic kit for monitoring nonenzymatically galactated proteins in galactose. Classical galactose is a disorder of galactose metabolism caused by a deficiency of galactose-1-phosphate uridyltransferase. The resulting severe impairment of galactose metabolism has been recognized for half a century and the frequency of this disorder is estimated to be 1 in 40,000 births. Generally, the biochemical phenotype includ es elevated concentrations of galactose, galactose-l- phosphate and galactitol in tissue and body fluids. While the disease is generally fatal, treatment consisting of severe restriction of dietary galactose has proved life saving; nevertheless, most patie nts develop neurological abnormalities despite this diet. Earlier studies demonstrated the occurrence of elevated levels of glycated hemoglobin/albumin in galactosemia prompting the speculation that, akin to diabetes with glycated proteins, the monitoring of galactated proteins may prove useful for managing galactosemic patients. During Phase I, we will attempt to develop a monoclonal antibody probe directed to nonenzymatically galactated albumin that by standard immunological techniques will prove specific to galactated albumin. This probe will be then used in ELISA to establish its sensitivity and range of detection. Phase II efforts will focus on evaluating this ELISA in a clinical setting and optimizing its performance for the management of galactosemic patients. Phase III efforts will focus on the commercialization of this assay. Vandalia Research, Inc. is committed to manufacture, market and sell the diagnostic kit that will result from this research effort. Pediatricians and internists have long been w aiting for assays to monitor galactosemic patients; a method to quantify galactated proteins may provide a viable approach for preventing or delaying many of the complications of the disease including the onset of neurological damage during childhood and p ost adolescent years.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government